The PlasmaFlow is intended to be an easy to use sequential compression system, prescribed by a physician, for use in the home or clinical setting to help prevent the onset of DVT in patients by stimulating blood flow in the extremities (stimulating muscle contractions).
This device can be used to:
Portable, lightweight and tubeless
Long lasting re-chargeable battery. Up to 10 hours of use on one charge
2 Modes: Slow inflation and Step-Up Technology which allows the unit to increase pressure in slower increments
2 LCD screens to monitor usage and pressure
The critical post discharge period due to the medical necessity of increasing blood circulation and decreasing postoperative pain, swelling and inflammation. PlasmaFlow mobile compression system received FDA clearance and has proven clinical studies that show it is an effective non pharmacologic therapy for enhancement of blood circulation and or DVT Management. Clinical evidence has shown the PlasmaFlow mobile compression system to be as effective as low molecular weight heparins LMWH and to eliminate the anticoagulants serious bleeding complications. Significant published data is available on the incidents of DVT/PE, the effectiveness of various prophylactic techniques and the risks of hemorrhage when heparin is used, all of which provide positive and compelling evidence in support for the use of intermittent compression devices in VTE prevention.
The surgeons has prescribed the above system and certify that the PlasmaFlow mobile compression system device and supplies are medically necessary for the treatment of his patient’s care. The doctor has found that the PlasmaFlow mobile compression system improves the healing time and provides reduction of complications following orthopedic surgery. Recovery is quicker and subsequent physical therapy is more effective. The foregoing is per consensus from the guidelines for VTE Prophylaxis from the ACCP (American College of Chest Physicians); recommendations from AAOS (American Academy of Orthopedic Surgeons); and SCIP (Surgical Care Improvement Program).
Blood clots affect many people — people from all walks of life — and no one person is any less important than another. It’s difficult to look at the numbers below, and not think of the individuals — their families, their friends — and not ask oneself, “Could I be at risk for a blood clot?” The answer most certainly is, “Yes, anyone can affected by blood clots.” Blood clots do not discriminate.
Tragically, too many lives are affected by blood clots, and too many lives are lost because public awareness about life-threatening blood clots is so low. Study after study has shown that fewer than 1 in 4 people have any recognition of blood clots or their signs and symptoms.
— 107 to 130 cases of potentially deadly blood clots occurred each year per 100,000 Caucasian individuals from 1985 through 2002. This translates into about 1 to 3 cases per 1,000 people.
— 250,000 cases of potentially deadly blood clots, such as deep vein thrombosis or DVT, occurred each year between 1966 through 1990.
— 900,000 cases per year are now suggested by recent scientific modeling and public health statistics.
— 100,000 to 300,000 deaths from blood clots occur each year, which is greater than the total number of people who lose their lives each year to AIDS, breast cancer, and motor vehicle crashes combined.
— 600,000 non-fatal cases of deadly blood clots occur each year, of which 40% are blood clots in the lungs and 60% are blood clots in the legs
— 547,596 hospitalizations due to blood clots occurred from 2007 – 2009.